ConductScience.org, home
ROR1: ROR family WNT receptor 1
API referenceFor AI assistants

Gene · 4919

Papers2,258

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 2,258

Download this page as JSON
TitleJournalYearPMIDFound bySource
Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.Leukemia202642827116PubTator, text miningPubMed
SLV-404, an anti-RYK antibody-drug conjugate, is effective in Richter transformation patient-derived xenografts.Hemasphere202642824998PubTator, text miningPubMed
ROR1 upregulation after CD19-CAR T-cell relapse in mantle cell lymphoma identifies a targetable vulnerability for ROR1-directed bispecific modalities.Leukemia202642823506PubTator, text miningPubMed
Multipronged enhancement of CART cell activity against ROR1 neoantigen by inhibition of H3K27 methyltransferase EZH2.Cell Rep Med202642790422PubTator, text miningPubMed
Targeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma.Blood Neoplasia202642733493PubTator, text miningPubMed
Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1.MAbs202642731893PubTator, text miningPubMed
Surface expression of ROR1 across lymphoma cell lines identifies models for preclinical evaluation of ROR1-targeting antibody-drug conjugates.Leuk Lymphoma202642704791PubTator, text miningPubMed
Retraction notice to "Theranostic silk sericin/SPION nanoparticles for targeted delivery of ROR1 siRNA: Synthesis, characterization, diagnosis and anticancer effect on triple-negative breast cancer" [Int. J. Biol. Macromol. 221 (2022) 604-612].
Int J Biol Macromol202642686485PubTator, text miningPubMed
Comprehensive analysis of senescence-associated secretory phenotype-related signature for predicting prognosis and immunotherapy response in cervical cancer.Comput Methods Biomech Biomed Engin202642643048PubTator, text miningPubMed
Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer's Disease.Neurotox Res202642635855PubTator, text miningPubMed
Screening of potential antibody-drug conjugate (ADC) targets in neuroendocrine carcinoma of the cervix: implications for targeted therapy.J Gynecol Oncol202642625475PubTator, text miningPubMed
In vitro characterization of a novel anti-GD2/ROR1 bispecific antibody exhibiting tumor cell killing efficacy in neuroblastoma cross-cancer activity in ROR1-positive triple-negative breast cancer.Transl Cancer Res202642591885PubTator, text miningPubMed
Quantum Reactivity-Guided Optimization of ATP-Competitive Ligands through Multiscale Simulation.ACS Phys Chem Au202642565187PubTator, text miningPubMed
[Recent advances and future perspectives in the treatment of chronic lymphocytic leukemia].Rinsho Ketsueki202642543649PubTator, text miningPubMed
Imaging of ROR1 expression in tumors using radiolabeled affibody molecules.Eur J Nucl Med Mol Imaging202642538452PubTator, text miningPubMed
Development of novel nanoliposomes co-loaded with ROR1 inhibitor and Ce6 for the treatment of EGFR-TKIs resistant NSCLC by synergistic targeted inhibitor therapy and photodynamic therapy.J Photochem Photobiol B202642537451PubTator, text miningPubMed
Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts.Hemasphere202642488471PubTator, text miningPubMed
Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemia.BMC Med202642374527PubTator, text miningPubMed
Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.Cell Rep Med202642349416PubTator, text miningPubMed
The multifaceted roles of receptor tyrosine pseudokinases in cellular signalling.Biochem Soc Trans202642267535PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/4919/papers

API referenceFor AI assistants